Welcome to the Legend Biotech’s First Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer ...

Poster presentation to demonstrate EBT-107's potential to reduce clinically-relevant biomarkers and HBV DNA integration toward functiona ...

Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart DiseaseSOUTH SAN FRANCISCO, Calif., May ...

Data support planned dosing regimen and protocol for FIH study to initiate in mid-2025 LONDON, May 13, 2025 (GLOBE NEWSWIRE) ...

"The data we will present at ASGCT underscore the power and versatility of Encoded's vector engineering platform to target a wide array of validated disease pathways with potential one-time treatments ...

Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today presents IND- and CTA-enabling data for its lead clinical program, ...

Siren Biotechnology Inc., pioneers of Universal AAV Immuno-Gene Therapy for Cancer, today announced that it will present new ...

Presentations will be available on the Alterity Therapeutics website here.

AAVantgarde Bio (AAVantgarde), a clinical-stage international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces the ...

Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash ...

PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech” or the "Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and infectious ...